Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry.

A post hoc analysis of data from the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial in a subgroup of patients diagnosed with PAD showed a trend for a benefit of clopidogrel plus aspirin over aspirin alone in this population, with a reduction in MI rates. 19 , 34 At the time the REACH Registry was established, the novel oral antithrombotic agents prasugrel, ticagrelor, vorapaxar, or rivaroxaban were not available.

also in 53,322 other papers